Evotec’s subsidiary and CDMO, Just – Evotec Biologics, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to advance manufacturing optimisation for a monoclonal antibody cocktail. The therapy will target filovirus diseases, including Ebola virus (EBOV) and Sudan virus (SUDV). The multi-year programme award, valued at up […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!